Dauch Corporation (DCH) Q3 2026 Earnings Call Transcript

Dauch reported Q3 2026 sales of $2.91B and adjusted EBITDA of $358.5M, or a 12.3% margin, including the first full-quarter Dowlais contribution; adjusted EPS fell to $0.22 from $0.30 a year earlier. It raised full-year sales guidance to $10.8B–$10.875B, but cut adjusted EBITDA guidance to $1.35B–$1.375B amid inflation and customer production volatility, while reporting $100M in run-rate synergies after three full quarters. Adjusted free cash flow was $126.7M, net debt was $4.1B with 2.6x leverage, and management continues to target leverage below 2.0x.

Analysis

The key signal is deteriorating earnings quality beneath improved guidance optics: the sales increase is acquisition-led, while EBITDA guidance was cut despite a higher sales range. That points to near-term margin absorption—not demand growth—as the central underwriting issue. Energy and supplier cost recovery may lag into early 2027; meanwhile, supplier distress can become a production interruption risk for DCH and its OEM customers, not merely a purchasing-cost problem.

Synergies are real but front-loaded toward SG&A and engineering. The larger purchasing and plant-efficiency portions remain harder to capture, so extrapolating the current run-rate to the full $300 million target risks overstating sustainable earnings. At 2.6x leverage and a 7.1% average debt rate, execution delays have an amplified equity cost: interest absorbs cash that otherwise supports deleveraging. Capital-expenditure restraint helps near-term cash conversion but could limit productivity investment if prolonged.

GM launch downtime and weaker Ram Heavy Duty volumes tied to Stellantis expose DCH to customer-specific utilization swings. GM’s production plan is a support, not a guarantee; another schedule reset would pressure fixed-cost absorption. Over 6–18 months, the European footprint faces a separate utilization risk from Chinese OEM competition, partly offset if DCH converts its new customer relationships into profitable awards. The November 17 investor day is the next credibility test on synergy detail and restructuring needs. The transcript alone does not establish valuation or consensus expectations, so the earnings reaction is not enough to justify an outright short.

Key Decisions for Investors

• Keep DCH underweight / avoid adding on headline sales growth until organic volume, EBITDA margin, and net leverage show sequential improvement. Reassess after the next earnings report and the November 17 investor day.
• Treat the $300 million synergy target as execution-dependent, not as a near-term earnings run-rate: track separately disclosed purchasing and manufacturing savings, and compare realized savings with restructuring and integration cash outlays.
• Watch for a thesis-falsifying improvement: inflation recovery without renewed production disruption, stable or recovering margins, and continued debt paydown. Conversely, weaker customer schedules, further EBITDA guidance pressure, or stalled deleveraging would strengthen the cautious stance.
• No direct GM or Stellantis trade is supported by this call alone; confirm OEM production schedules and DCH customer/program exposure before translating supplier volatility into an OEM position.